Free Trial
NASDAQ:PMN

ProMIS Neurosciences Q4 2024 Earnings Report

ProMIS Neurosciences logo
$0.65 0.00 (-0.62%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ProMIS Neurosciences EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

ProMIS Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ProMIS Neurosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

ProMIS Neurosciences' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Monday, May 12, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ProMIS Neurosciences Earnings Headlines

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
Trump Makes Major Crypto Announcement
Trump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick.
See More ProMIS Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProMIS Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProMIS Neurosciences and other key companies, straight to your email.

About ProMIS Neurosciences

ProMIS Neurosciences (NASDAQ:PMN) discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

View ProMIS Neurosciences Profile

More Earnings Resources from MarketBeat